Literature DB >> 12241930

Resistance to reinfection with Schistosoma mansoni in occupationally exposed adults and effect of HIV-1 co-infection on susceptibility to schistosomiasis: a longitudinal study.

Diana M S Karanja1, Allen W Hightower, Daniel G Colley, Pauline N M Mwinzi, Karin Galil, Julius Andove, W Evan Secor.   

Abstract

BACKGROUND: Previous studies have reported age-dependent development of resistance to reinfection by schistosomes and identified immunological correlates of this resistance. However, whether resistance exists that is independent of age effects has been questioned. We did a longitudinal investigation of reinfection by Schistosoma mansoni in an adult population with high occupational exposure.
METHODS: We monitored a cohort of 96 male car washers working along the shores of Lake Victoria, Kenya during 349.7 person-years for frequency of water contact and infection with S mansoni. Patients were treated with praziquantel upon study entry and after reinfection with S mansoni. Bivariate analyses and a multivariate proportional hazards model were used to assess the effects of water contact, previous infections, and HIV-1 on S mansoni reinfection rates.
FINDINGS: 13 car washers did not get reinfected or only became reinfected after an extended time (91 weeks). 47 initially had a short time to reinfection (15 weeks) but on subsequent treatments showed increased time to reinfection (29-38 weeks). 36 consistently displayed short times to reinfection (<15 weeks) despite multiple reinfection and treatment cycles. Decreased CD4 T-cell counts in HIV-1-positive individuals corresponded to increased susceptibility to S mansoni reinfection.
INTERPRETATION: Adults similarly exposed to schistosomiasis are either resistant to reinfection; susceptible, but develop resistance to reinfection after multiple treatments; or remain susceptible to reinfection. Thus, immunological resistance to reinfection with S mansoni exists or can develop independent of age effects. The consequence of HIV-1 co-infection suggests that CD4 T cells contribute to this resistance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12241930     DOI: 10.1016/S0140-6736(02)09781-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  65 in total

1.  Factors associated with resistance to Schistosoma mansoni infection in an endemic area of Bahia, Brazil.

Authors:  Ricardo R Oliveira; Joanemile P Figueiredo; Luciana S Cardoso; Rafael L Jabar; Robson P Souza; Martin T Wells; Edgar M Carvalho; Daniel W Fitzgerald; Kathleen C Barnes; Maria Ilma Araújo; Marshall J Glesby
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

2.  Immuno-evasive tactics by schistosomes identify an effective allergy preventative.

Authors:  Qyana Griffith; YanMei Liang; Patrick Whitworth; Carlos Rodriguez-Russo; Ahmad Gul; Afzal A Siddiqui; John Connor; Pauline Mwinzi; Lisa Ganley-Leal
Journal:  Exp Parasitol       Date:  2015-03-24       Impact factor: 2.011

3.  Association of Schistosomiasis and HIV infection in Tanzania.

Authors:  Jennifer A Downs; Govert J van Dam; John M Changalucha; Paul L A M Corstjens; Robert N Peck; Claudia J de Dood; Heejung Bang; Aura Andreasen; Samuel E Kalluvya; Lisette van Lieshout; Warren D Johnson; Daniel W Fitzgerald
Journal:  Am J Trop Med Hyg       Date:  2012-10-01       Impact factor: 2.345

4.  Circulating CD23+ B cell subset correlates with the development of resistance to Schistosoma mansoni reinfection in occupationally exposed adults who have undergone multiple treatments.

Authors:  Pauline N M Mwinzi; Lisa Ganley-Leal; Carla L Black; W Evan Secor; Diana M S Karanja; Daniel G Colley
Journal:  J Infect Dis       Date:  2009-01-15       Impact factor: 5.226

Review 5.  Current status of vaccines for schistosomiasis.

Authors:  Donald P McManus; Alex Loukas
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

6.  A new approach to characterize populations of Schistosoma mansoni from humans: development and assessment of microsatellite analysis of pooled miracidia.

Authors:  B Hanelt; M L Steinauer; I N Mwangi; G M Maina; L E Agola; G M Mkoji; E S Loker
Journal:  Trop Med Int Health       Date:  2009-01-28       Impact factor: 2.622

Review 7.  Development of a schistosomiasis vaccine.

Authors:  Adebayo J Molehin; Juan U Rojo; Sabrina Z Siddiqui; Sean A Gray; Darrick Carter; Afzal A Siddiqui
Journal:  Expert Rev Vaccines       Date:  2016-01-13       Impact factor: 5.217

8.  Influence of exposure history on the immunology and development of resistance to human Schistosomiasis mansoni.

Authors:  Carla L Black; Pauline N M Mwinzi; Erick M O Muok; Bernard Abudho; Colin M Fitzsimmons; David W Dunne; Diana M S Karanja; W Evan Secor; Daniel G Colley
Journal:  PLoS Negl Trop Dis       Date:  2010-03-23

9.  Effects of treatment on IgE responses against parasite allergen-like proteins and immunity to reinfection in childhood schistosome and hookworm coinfections.

Authors:  Angela Pinot de Moira; Frances M Jones; Shona Wilson; Edridah Tukahebwa; Colin M Fitzsimmons; Joseph K Mwatha; Jeffrey M Bethony; Narcis B Kabatereine; David W Dunne
Journal:  Infect Immun       Date:  2012-10-15       Impact factor: 3.441

10.  Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni.

Authors:  Sandra D Melman; Michelle L Steinauer; Charles Cunningham; Laura S Kubatko; Ibrahim N Mwangi; Nirvana Barker Wynn; Martin W Mutuku; Diana M S Karanja; Daniel G Colley; Carla L Black; William Evan Secor; Gerald M Mkoji; Eric S Loker
Journal:  PLoS Negl Trop Dis       Date:  2009-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.